Diabetes news from FierceBiotech
NewsFDA panel backs added risk review on diabetes drugs
A FDA advisory panel has voted 14-2 to recommend that the developers of diabetes drugs specifically demonstrate that their experimental therapies don't increase cardiovascular risks. And if as Read more...
FDA considers new trial standard for diabetes drugs
In a move that could have enormously costly implications for developers of new diabetes therapeutics, Pharmalot reports that the FDA has asked its Endocrinologic and Metabolic Drugs Advisory Read more...
Sanofi: Acomplia demonstrates better glucose control
Sanofi-Aventis said that a trial of Acomplia showed a significant improvement in glucose control in comparison to insulin among patients with type 2 diabetes. Glucose control was three times more Read more...
DPP-4 inhibitors get spotlight at ADA meeting
Researchers are unveiling positive data at the American Diabetes Association's meeting for new DPP-4 inhibitors for diabetes. Takeda is the latest, demonstrating that its alogliptin can control blood Read more...
ALSO NOTED: ASCO already churning out news; Lilly, FDA ironing out Zyprexa shot problems; and much more...
> Today marks the start of the annual ASCO. Here's a round-up of some of the news coming out of the conference. Read more...
EmergingMed matches patients with clinical trials
Recruiting the right number of the right patients for any clinical trial can be a tough prospect. Now there are a host of new efforts to match a patient with a clinical trial, including a service Read more...
Pfizer builds plant, creates jobs in Ireland
Pfizer has finally confirmed earlier reports about its plan to Read more...
SPOTLIGHT: Biocon establishing R&D sub
India's Biocon says it will transfer four molecules to a new R&D subsidiary, resisting a trend in the subcontinent of spinning off R&D into a new company. Its researchers are working on new Read more...
AtheroGenics shares soar on diabetes data
Shares of AtheroGenics shot up this morning on the news that an interim analysis of late-stage data for Read more...
Keryx triggers big shakeup to counter trial fiasco
Less than a month after seeing its lead drug candidate go down in flames in a late-stage trial, Keryx Read more...
| Press ReleasesPRESS RELEASE: AtheroGenics Says Stops Highest Dose of Drug in Diabetes Trial AtheroGenics Says Stops Highest Dose of Drug in Diabetes Trial ATLANTA, GA -- Nov 9, 2007 -- AtheroGenics, today announced that after discussions with the U.S. Food and Drug Administration (FDA), Read more... PRESS RELEASE: Isis Adds New Drug to Its Development Pipeline: ISIS 388626 Isis Adds New Drug to Its Development Pipeline: ISIS 388626 Targeting SGLT2 for the Treatment of Type 2 Diabetes CARLSBAD, Calif., Oct. 18 -- Isis Pharmaceuticals, Inc. today announced that it has Read more... PRESS RELEASE: Eli Lilly and Company in $494 Million Deal for Diabetes Drug Eli Lilly and Company in $494 Million Deal for Diabetes Drug ROCKVILLE, Md., and INDIANAPOLIS, Oct. 18 -- Eli Lilly and Company and MacroGenics, Inc. today announced that the two companies have Read more... PRESS RELEASE: Exelixis Diabetic Nephropathy Drug Trial Fails Goal Exelixis Diabetic Nephropathy Drug Trial Fails Goal SOUTH SAN FRANCISCO, Calif., Oct. 16 -- Exelixis announced that a recently completed phase 2 trial of XL784 did not meet its primary endpoint of Read more... |
Get more Diabetes coverage at:
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends